On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of ມະເລັງປອດ conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumor cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb ເປີດເຜີຍວ່າບໍລິສັດໄດ້ສົ່ງຄໍາຮ້ອງສະຫມັກຂອງ Opdivo ສໍາລັບການປິ່ນປົວຕົວຊີ້ວັດມະເຮັງປອດຕໍ່ FDA ແລະການບໍລິຫານຢາຂອງ EU. ແນ່ນອນ, ບໍລິສັດ Squibb ທີ່ທະເຍີທະຍານໂດຍທໍາມະຊາດຈະບໍ່ພຽງແຕ່ພໍໃຈກັບມະເຮັງປອດແລະ melanoma. ໃນຄວາມເປັນຈິງ, Squibb ກໍາລັງດໍາເນີນການຫຼາຍກ່ວາ 35 ການສຶກສາຂອງ Opdivo ດຽວຫຼືປະສົມປະສານກັບຢາອື່ນໆເພື່ອປິ່ນປົວປະເພດ tumor ທີ່ແຕກຕ່າງກັນ. ອີງຕາມນັກວິເຄາະ, ການຂາຍໃນອະນາຄົດຂອງ Opdivo ຈະບັນລຸເຖິງ 5 ຕື້ໂດລາສະຫະລັດ.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
ລາຍງານພາສາອັງກິດລາຍລະອຽດ:
Bristol-Myers Squibb's ($ BMY) standout immuno-o ncology drug nivolumab, ໄດ້ຮັບການອະນຸມັດໃນເດືອນທີ່ຜ່ານມາເປັນ Opdivo, ໄດ້ຄະແນນຜົນສໍາເລັດອັນຍິ່ງໃຫຍ່ໃນການທົດລອງມະເຮັງປອດໃນໄລຍະທ້າຍ, ຊຸກຍູ້ຄວາມຄາດຫວັງຂອງການຂາຍສໍາລັບການປິ່ນປົວ pio neering.
ໃນການສຶກສາຂອງຄົນເຈັບ 272 ຄົນ pitting Opdivo ຕໍ່ກັບ docetaxel ມາດຕະຖານຢາຂ້າມະເຮັງ, ການສາທິດຢາ Bristol-Myers ສະແດງໃຫ້ເຫັນເຖິງການຢູ່ລອດໂດຍລວມທີ່ເຫນືອກວ່າເມື່ອທຽບໃສ່ກັບ co ntrol arm ທີ່ມັນຕີຈຸດສຸດທ້າຍຕົ້ນຕໍກ່ອນກໍານົດເວລາ, ນໍາພາຂໍ້ມູນຂອງການທົດລອງ mo nitoring committee ແນະນໍາ. ການສຶກສາໄດ້ຖືກຢຸດເຊົາໄວ. ດຽວນີ້ Bristol-Myers ກໍາລັງເຊື້ອເຊີນຄົນເຈັບໃນກຸ່ມ docetaxel ໃຫ້ເລືອກເອົາ Opdivo ຜ່ານການສຶກສາການຂະຫຍາຍປ້າຍຊື່ເປີດ.
ການປິ່ນປົວຂອງ Bristol-Myers ໄດ້ຖືກອອກແບບເພື່ອ galvanize ການໂຈມຕີລະບົບພູມຕ້ານທານຂອງເນື້ອງອກໂດຍການຂັດຂວາງເສັ້ນທາງທີ່ເອີ້ນວ່າ PD-1, ເຊິ່ງ, ເຊິ່ງບໍ່ຖືກກວດສອບ, ອະນຸຍາດໃຫ້ຈຸລັງມະເຮັງຜ່ານລະບົບປ້ອງກັນທໍາມະຊາດຂອງຮ່າງກາຍໂດຍບໍ່ໄດ້ກວດພົບ. ເຊັ່ນດຽວກັນກັບ Keytruda ຂອງ Merck ($ MRK) ທີ່ຄ້າຍຄືກັນ, Opdivo ໄດ້ຮັບການອະນຸມັດຈາກ FDA ໃນປີກາຍນີ້ເປັນການປິ່ນປົວສໍາລັບ melanoma, ແຕ່ຢາຂອງ Bristol-Myers ຢືນຢູ່ຄົນດຽວໃນມະເຮັງປອດ, ຍ້ອນວ່າຜົນສໍາເລັດທາງດ້ານຄລີນິກຫລ້າສຸດຂອງຕົນເປັນຄັ້ງທໍາອິດທີ່ຢາຍັບຍັ້ງ PD-1 ໄດ້ກໍານົດຕາຕະລາງ. ປະໂຫຍດດ້ານການຢູ່ລອດຕໍ່ກັບພະຍາດ, ບໍລິສັດກ່າວວ່າ.
Opdivo’s particular promise in ມະເລັງປອດທີ່ບໍ່ແມ່ນຈຸລັງນ້ອຍ has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers ໄດ້ສົ່ງຄໍາຮ້ອງສະຫມັກມະເຮັງປອດໃນສະຫະລັດແລະເອີຣົບສໍາລັບ Opdivo ໃນມະເຮັງປອດ, ຄາດວ່າຈະຂະຫຍາຍການນໍາໃຊ້ຢາໃນທ້າຍປີນີ້.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, ມະເຮັງຫົວແລະຄໍ, glioblastoma, Non-Hodgkin lymphoma and other cancers.
